Study Part 1: KRP203 + Study Part 2: KRP203 lower dose + Study Part 2: KRP203 higher dose
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematological Malignancies
Conditions
Hematological Malignancies
Trial Timeline
Jun 28, 2013 → Aug 21, 2018
NCT ID
NCT01830010About Study Part 1: KRP203 + Study Part 2: KRP203 lower dose + Study Part 2: KRP203 higher dose
Study Part 1: KRP203 + Study Part 2: KRP203 lower dose + Study Part 2: KRP203 higher dose is a phase 1 stage product being developed by Novartis for Hematological Malignancies. The current trial status is completed. This product is registered under clinical trial identifier NCT01830010. Target conditions include Hematological Malignancies.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01830010 | Phase 1 | Completed |
Competing Products
20 competing products in Hematological Malignancies